These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 22686875)

  • 21. Renal medullary carcinoma in a young mixed-race man in Japan.
    Toriyama A; Izumi H; Tomita S; Nagashima Y; Ueda Y; Aoki Y; Tsujimura A; Yao T; Hino O
    Pathol Int; 2019 Apr; 69(4):241-245. PubMed ID: 30843648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced expression of SMARCB1/INI1 protein in synovial sarcoma.
    Kohashi K; Oda Y; Yamamoto H; Tamiya S; Matono H; Iwamoto Y; Taguchi T; Tsuneyoshi M
    Mod Pathol; 2010 Jul; 23(7):981-90. PubMed ID: 20305614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases.
    Jia L; Carlo MI; Khan H; Nanjangud GJ; Rana S; Cimera R; Zhang Y; Hakimi AA; Verma AK; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE; Gartrell BA; Chen YB
    Mod Pathol; 2019 Sep; 32(9):1329-1343. PubMed ID: 30980040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity.
    Agaimy A
    Adv Anat Pathol; 2014 Nov; 21(6):394-410. PubMed ID: 25299309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss.
    Tsikitis M; Zhang Z; Edelman W; Zagzag D; Kalpana GV
    Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12129-34. PubMed ID: 16099835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Approach for reclassification of collecting duct carcinoma and comparative histopathological analysis with SMARCB1/INI1-deficient renal cell carcinoma and fumarate hydratase-deficient renal cell carcinoma.
    Kiyozawa D; Kohashi K; Takamatsu D; Iwasaki T; Shibata D; Tomonaga T; Tateishi Y; Eto M; Kinjo M; Nishiyama K; Taguchi K; Oshiro Y; Kuboyama Y; Furuya M; Oda Y
    Hum Pathol; 2022 Jun; 124():36-44. PubMed ID: 35306021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma.
    Papp G; Changchien YC; Péterfia B; Pecsenka L; Krausz T; Stricker TP; Khoor A; Donner L; Sápi Z
    Mod Pathol; 2013 Mar; 26(3):393-403. PubMed ID: 23174932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal medullary carcinomas depend upon
    Hong AL; Tseng YY; Wala JA; Kim WJ; Kynnap BD; Doshi MB; Kugener G; Sandoval GJ; Howard TP; Li J; Yang X; Tillgren M; Ghandi M; Sayeed A; Deasy R; Ward A; McSteen B; Labella KM; Keskula P; Tracy A; Connor C; Clinton CM; Church AJ; Crompton BD; Janeway KA; Van Hare B; Sandak D; Gjoerup O; Bandopadhayay P; Clemons PA; Schreiber SL; Root DE; Gokhale PC; Chi SN; Mullen EA; Roberts CW; Kadoch C; Beroukhim R; Ligon KL; Boehm JS; Hahn WC
    Elife; 2019 Mar; 8():. PubMed ID: 30860482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.
    Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM
    Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Ohe C; Smith SC; Sirohi D; Divatia M; de Peralta-Venturina M; Paner GP; Agaimy A; Amin MB; Argani P; Chen YB; Cheng L; Colecchia M; Compérat E; Werneck da Cunha I; Epstein JI; Gill AJ; Hes O; Hirsch MS; Jochum W; Kunju LP; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Nesi G; Osunkoya AO; Picken MM; Rao P; Reuter VE; de Oliveira Salles PG; Schultz L; Tickoo SK; Tomlins SA; Trpkov K; Amin MB
    Am J Surg Pathol; 2018 Mar; 42(3):279-292. PubMed ID: 29309300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type 1 papillary renal cell carcinoma in a patient with schwannomatosis: Mosaic versus loss of SMARCB1 expression in respectively schwannoma and renal tumor cells.
    Hulsebos TJ; Kenter S; Baas F; Nannenberg EA; Bleeker FE; van Minkelen R; van den Ouweland AM; Wesseling P; Flucke U
    Genes Chromosomes Cancer; 2016 Apr; 55(4):350-4. PubMed ID: 26799435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
    Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
    Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review.
    Agaimy A; Rau TT; Hartmann A; Stoehr R
    Am J Surg Pathol; 2014 Jul; 38(7):910-20. PubMed ID: 24503755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary epithelioid sarcoma of bone: report of a unique case, with immunohistochemical and fluorescent in situ hybridization confirmation of INI1 deletion.
    Raoux D; Péoc'h M; Pedeutour F; Vaunois B; Decouvelaere AV; Folpe AL
    Am J Surg Pathol; 2009 Jun; 33(6):954-8. PubMed ID: 19342946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma.
    Msaouel P; Tannir NM; Walker CL
    Clin Cancer Res; 2018 May; 24(9):2044-2049. PubMed ID: 29440190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathology and diagnosis of SMARCB1-deficient tumors.
    Margol AS; Judkins AR
    Cancer Genet; 2014 Sep; 207(9):358-64. PubMed ID: 25246033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case Report: Unclassified Renal Cell Carcinoma With Medullary Phenotype and
    Valeri M; Cieri M; Elefante GM; De Carlo C; Rudini N; Lughezzani G; Buffi NM; Terracciano LM; Colombo P
    Front Med (Lausanne); 2022; 9():835599. PubMed ID: 35198580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas.
    Patil S; Perry A; Maccollin M; Dong S; Betensky RA; Yeh TH; Gutmann DH; Stemmer-Rachamimov AO
    Brain Pathol; 2008 Oct; 18(4):517-9. PubMed ID: 18422762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malignant Ossifying Fibromyxoid Tumors: a report of two rare cases displaying retained INI1/SMARCB1 expression.
    Rekhi B; Thorat S; Parikh G; Jambhekar NA
    Indian J Pathol Microbiol; 2014; 57(4):652-3. PubMed ID: 25308036
    [No Abstract]   [Full Text] [Related]  

  • 40. High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors.
    Hasselblatt M; Isken S; Linge A; Eikmeier K; Jeibmann A; Oyen F; Nagel I; Richter J; Bartelheim K; Kordes U; Schneppenheim R; Frühwald M; Siebert R; Paulus W
    Genes Chromosomes Cancer; 2013 Feb; 52(2):185-90. PubMed ID: 23074045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.